Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis

被引:3
|
作者
Takei, Reoto [1 ]
Matsuda, Toshiaki [1 ]
Fukihara, Jun [1 ]
Sasano, Hajime [1 ]
Yamano, Yasuhiko [1 ]
Yokoyama, Toshiki [1 ]
Kataoka, Kensuke [1 ]
Kimura, Tomoki [1 ]
Suzuki, Atsushi [2 ]
Furukawa, Taiki [2 ,3 ]
Fukuoka, Junya [4 ]
Johkoh, Takeshi [5 ]
Kondoh, Yasuhiro [1 ]
机构
[1] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Japan
[3] Nagoya Univ Hosp, Med IT Ctr, Nagoya, Japan
[4] Nagasaki Univ Hosp, Dept Pathol, Nagasaki, Japan
[5] Kansai Rosai Hosp, Dept Radiol, Amagasaki, Japan
关键词
interstitial lung disease; progressive pulmonary fibrosis; progressive fibrosing interstitial lung disease; St George's respiratory questionnaire; COPD assessment test; health-related quality of life; 6 min walk distance; COPD ASSESSMENT TEST; HEALTH-STATUS; VALIDITY; 1ST;
D O I
10.3389/fmed.2023.1067149
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundHealth-related quality of life (HRQoL) captures different aspects of the fibrotic interstitial lung disease (FILD) evaluation from the patient's perspective. However, little is known about how HRQoL changes in patients with non-idiopathic pulmonary fibrosis (IPF) FILD, especially in those with progressive pulmonary fibrosis (PPF). The aim of this study is to clarify whether HRQoL deteriorates in patients with non-IPF FILD and to evaluate the differences in the changes in HRQoL between those with and without PPF. MethodsWe collected data from consecutive patients with non-IPF FILD and compared annual changes in HRQoL over 2 years between patients with PPF and those without. The St George's respiratory questionnaire (SGRQ) and COPD assessment test (CAT) were used to assess HRQoL. Changes in the SGRQ and CAT scores for 24 months from baseline were evaluated with a mixed-effect model for repeated measures. ResultsA total of 396 patients with non-IPF FILD were reviewed. The median age was 65 years and 202 were male (51.0%). The median SGRQ and CAT scores were 29.6 and 11, respectively. Eighty-six (21.7%) showed PPF. Both SGRQ and CAT scores were significantly deteriorated in patients with PPF compared to those without PPF (p < 0.01 for both). Clinically important deterioration in the SGRQ and CAT scores were observed in 40.0 and 35.7% of patients with PPF and 11.7 and 16.7% of those without, respectively. PPF was significantly associated with clinically important deterioration in the SGRQ score (odds ratio 5.04; 95%CI, 2.61-9.76, p < 0.01) and CAT score (odds ratio 2.78; 95%CI, 1.27-6.06, p = 0.02). ConclusionThe SGRQ and CAT scores were significantly deteriorated in patients with non-IPF FILD and PPF. Considering an evaluation of HRQoL would be needed when assessing PPF.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Outcome of lung transplantation in non-idiopathic pulmonary fibrosis interstitial lung disease
    Bode, Hannelore
    Verleden, Stijn E.
    Wuyts, Wim A.
    Yserbyt, Jonas
    Verleden, Geert M.
    Vos, Robin
    CLINICAL TRANSPLANTATION, 2019, 33 (10)
  • [2] Cluster phenotypes in a non-idiopathic pulmonary fibrosis fibrotic interstitial lung diseases cohort in Singapore
    Kam, Michelle Li Wei
    Tiew, Pei Yee
    Chai, Hui Zhong
    Low, Su Ying
    JOURNAL OF THORACIC DISEASE, 2022, : 2481 - 2492
  • [3] Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
    Zhang, David
    Adegunsoye, Ayodeji
    Oldham, Justin M.
    Kozlitina, Julia
    Garcia, Nicole
    Poonawalla, Maria
    Strykowski, Rachel
    Linderholm, Angela L.
    Ley, Brett
    Ma, Shwu-Fan
    Noth, Imre
    Strek, Mary E.
    Wolters, Paul J.
    Garcia, Christine Kim
    Newton, Chad A.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (05)
  • [4] Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
    Mackintosh, John A.
    Chambers, Daniel C.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 63 (01)
  • [5] Evaluation of progressive pulmonary fibrosis in non-idiopathic pulmonary fibrosis-interstitial lung diseases: a cross-sectional study
    Diken, Ozlem Ercen
    Gungor, Omur
    Akkaya, Huseyin
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [6] Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Research
    Swigris, Jeffrey J.
    Fairclough, Diane
    CHEST, 2012, 142 (02) : 291 - 297
  • [7] Reply: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
    Zhang, David
    Adegunsoye, Ayodeji
    Oldham, Justin M.
    Wolters, Paul J.
    Garcia, Christine Kim
    Newton, Chad A.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 63 (01)
  • [8] Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases
    Dhooria, Sahajal
    Agarwal, Ritesh
    Gupta, Dheeraj
    LUNG INDIA, 2015, 32 (01) : 4 - +
  • [9] Endotyping idiopathic pulmonary fibrosis should improve outcomes for all patients with progressive fibrotic lung disease
    Jenkins, Gisli
    THORAX, 2015, 70 (01) : 9 - 10
  • [10] Patient-Reported Outcomes in Idiopathic Pulmonary Fibrosis in The Geriatric Population
    Parks, K. R.
    Osevala, N.
    Dimmock, A.
    Bascom, R.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2018, 66 : S312 - S312